Moderna Covid-19 vaccine approved by MHRA in 12-to-17-year-olds

An extension to the current UK approval of the Spikevax vaccine, formerly the Covid-19 Vaccine Moderna, that allows its use in 12-to 17-year-olds has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).

This Conditional Marketing Authorisation extension granted by the MHRA is valid in Great Britain only and was approved via the European Commission Decision Reliance Route. That is when the marketing authorisation application made by the company references the decision made by the EMA’s Committee for Medicinal Products for Human Use.

Dr June Raine, MHRA Chief Executive said, “I am pleased to confirm that that the Covid-19 vaccine made by Moderna has now been authorised in 12-to-17-year-olds. The vaccine is safe and effective in this age group.

“We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved COVID-19 vaccines and this surveillance will include the 12- to 17-year age group.

“It is for the Joint Committee on Vaccination and Immunisation to advise on whether this age group should be vaccinated with the Covid-19 vaccine made by Moderna as part of the deployment programme,” she added on August 17.

Spikevax is authorised in children aged 12-17 years in Northern Ireland under an extension granted by the European Medicines Agency on 23 July 2021.

Thank you for taking the time to read this article, please remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and follow us on Facebook and Instagram.